No disease-modifying therapies (DMTs) are approved for nonrelapsing, progressive forms of MS, which comprise the majority of chronic progressive multiple sclerosis (CP-MS) patients. Current treatment relies heavily on off-label use of products approved for the treatment of relapsing forms of MS, or anti-inflammatory agents that are not approved at all for MS. This Unmet Need content provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need in CP-MS. We analyze the commercial opportunities and how emerging therapies may capitalize on these opportunities.

Table of contents

  • Multiple Sclerosis - Unmet Need - Detailed, Expanded Analysis Chronic Progressive Multiple Sclerosis
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in CP-MS
        • Importance of Efficacy Attributes to Prescribing Decisions in CP-MS — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in CP-MS — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in CP-MS — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in CP-MS — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in CP-MS — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in CP-MS — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in CP-MS — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in CP-MS — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Chronic-Progressive Multiple Sclerosis
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for CP-MS — United States
        • Overall Performance of Key Therapies for CP-MS — Europe
        • Relative Performance of Key Therapies for CP-MS Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for CP-MS Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for CP-MS Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for CP-MS Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for CP-MS Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for CP-MS Across Select Convenience of Administration Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Neurologists' Satisfaction With the Performance of Key Therapies for CP-MS on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Neurologists' Satisfaction With the Performance of Key Therapies for CP-MS on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Chronic-Progressive Multiple Sclerosis
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in CP-MS — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in CP-MS — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in CP-MS — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in CP-MS — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in CP-MS — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in CP-MS — Europe
      • Unmet Need in CP-MS and Related Indications
        • Surveyed Neurologists' Ascribed Level of Unmet Need in CP-MS and Related Indications — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in CP-MS and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the CP-MS Market and Emerging Therapy Insights
        • Opportunity: A Novel DMT Approved to Treat Primary-Progressive Multiple Sclerosis
        • Opportunity: A Novel DMT Approved to Treat Secondary-Progressive Multiple Sclerosis
        • Opportunity: A Novel DMT Approved Broadly for Progressive Multiple Sclerosis (e.g., CP-MS)
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • PP-MS Target Product Profile: Attribute Importance
        • PP-MS Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • PP-MS Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • PP-MS Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • PP-MS Market Simulations: Target Product Profiles Included in Scenario 1
        • PP-MS Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • PP-MS Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • PP-MS Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Dr. Ankuri Setia, BDS, PGDHM

Dr. Ankuri Setia is a Biopharma Insight Analyst in the CNS team at Decision Resources Group.

She comes with a work experience of 2 years as Knowledge Management Associate with practice across multiple therapy areas and indications on various functions in secondary research, competitive intelligence and product profiling, market assessment and pipeline analysis, and clinical trials assessment. She earned a Master of Healthcare Management degree from Institute of Health Management Research, a Deemed University.


Related Reports

Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

View Details

Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

View Details

Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

View Details